Comparison of clinical efficacy of TMF and TDF in the treatment of hepatitis B liver fibrosis
10.3969/j.issn.1006-5725.2024.22.016
- VernacularTitle:艾米替诺福韦和富马酸替诺福韦对治疗乙肝肝纤维化的临床疗效比较
- Author:
Yingyuan ZHANG
1
;
Chunyan MOU
;
Danqing XU
;
Yuanzhen WANG
;
Lixian CHANG
;
Chunyun LIU
;
Weikun LI
;
Hong-Yan WEI
;
Li LIU
Author Information
1. 昆明市第三人民医院云南省传染性疾病临床医学中心(云南 昆明 650041)
- Keywords:
tenofovir amibufenamide;
tenofovir disoproxil fumarate;
interferon;
clinical efficacy;
liver fibrosis
- From:
The Journal of Practical Medicine
2024;40(22):3215-3220
- CountryChina
- Language:Chinese
-
Abstract:
Objective This study is to explore the clinical efficacy and common adverse reactions of PEG-IFN α-2b combined with TMF and TDF in the treatment of hepatitis B liver fibrosis,and provide more clinical reference for the treatment of chronic hepatitis B.Methods From January 2022 to December 2023,we selected 130 patients with chronic hepatitis B liver fibrosis who were admitted to Kunming Third People's Hospital.Divided into TMF combined group and TDF combined group,the virus reduction level,virus response rate,liver fibrosis four items,instantaneous elastography(FibroScan)and other indicators were compared between the two groups of patients after 48 weeks of treatment.The changes in liver fibrosis grading and adverse reactions before and after treatment were also compared.Results After 48 weeks of treatment,the TMF combined group showed a significant increase in HBV DNA seroconversion rate and HBeAg seroconversion rate compared to the TDF combined group,with statistical significance(P<0.05).However,there was no statistically significant difference in HBsAg seroconversion rate between the two groups of patients(P>0.05).After 48 weeks of treatment,the TMF combined group showed more significant efficacy in reducing the levels of HA,PC Ⅲ,Ⅳ-C,and LN,with a significant difference(P<0.05);After 48 weeks of treatment,both groups of patients showed improvement in the degree of liver tissue fibrosis.Compared with the TDF combined group,the TMF combined group had a more significant effect on tissue improvement.After 48 weeks of treatment,the incidence of dyslipidemia,hypothyroidism,and diarrhea was higher in the TMF combined group than in the TDF combined group(P<0.05);After 48 weeks of treatment,there was no statistically significant difference in the incidence of gingival bleeding,anemia,and thrombocytopenia between the two groups of patients(P>0.05);The incidence of elevated uric acid and joint pain in the TDF combined group was higher than that in the TMF combined group after 48 weeks of treatment(P<0.05).Conclusion TMF combined with PEG-IFN α-2b has better clinical efficacy in treating chronic hepatitis B,strong antiviral ability,greater inhibition of liver fibrosis,good drug safety,better prognosis,and can provide more effective medication basis for clinical cure of hepatitis B.
